SCN SIGNS EXCLUSIVE AGREEMENT FOR COLDIZIN IN THE UK AND IRELAND
(NGM:SCN)
Scandinavian Clinical Nutrition AB (SCN) has entered into an exclusive distribution and supply agreement for the patented and trademark protected product Coldizin in the UK, Ireland and Channel Islands with Vital Life International Ltd.
“The UK is a key European market for SCN to break into, and I am looking forward to launching our unique, clinically documented product Coldizin in collaboration with a competent partner like Vital Life”, says Danilo Copiz, VP Sales at SCN.
Vital Life International, Ltd. is a UK based company whose management has extensive experience from the whole supply chain in the health and supplement industry, from purchasing to marketing, PR and sales, including a dedicated PR agency ready to take on product marketing and branding projects. They are specialized in launching and managing healthcare brands in the UK.
“Scandinavian Clinical Nutrition is pre-eminent in its field of producing clinically proven nutraceuticals and supplements. Vital Life is delighted to be appointed by SCN as its new distribution partner for the UK and Irish market places, and looks forward to introducing an exciting and growing portfolio of unique products designed to offer consumers enhanced health and well being benefits. Vital Life is particularly well placed to deliver for SCN as a result of invaluable synergies with its sister company relationship with Fuel PR International, one of the UK’s leading health and well being PR consultancies with a very strong track record for innovative and powerful communications campaigns”, says Gillian Waddell, Managing Director at Vital Life.
Under the agreement, Vital Life will be responsible for product marketing and promotion, as well as local regulatory issues, supported by the expertise from SCN.
For more information, please contact:
Danilo Copiz, VP Sales, dc@scnutrition.com, +45 2090 8885
Ulf Söderberg, CEO, us@scnutrition.com, +46 708 13 22 81
Scandinavian Clinical Nutrition AB (publ) is engaged in R&D and distribution of clinically tested, scientifically documented products within the field of nutrition (nutraceuticals). Established in 2006, SCN maintains a product portfolio with established trademarks, such as CUUR, Coldizin, Immulina, Membra7 and Ledactin. Core competence and strategic alliances, within both R&D and sales, in combination with innovative and clinically proven products, create good conditions for profitable growth both in Scandinavia and internationally. The shares of SCN are traded under the ticker “SCN” on Oslo Axess (www.osloaxess.no ) and NGM Equity (www.ngm.se). For more information, please visit www.scnutrition.com.